Presented at the Annual Meeting of the Association for Academic Surgery, Houston, Texas, November 14-17, 1990 Neuropeptide Y (NPY) is a unique peptide with wide distribution in central and peripheral nervous systems. In the guinea pig, NPY-positive fibers are prominent in the myenteric plexus.
To test whether NPY inhibits myenteric plexus acetylcholine (ACh) release and to define mechanisms, a purified preparation of myenteric plexus neurons was derived from the teniae coli of neonatal guinea pigs and maintained in primary culture. Incubation of cultured neurons labeled with [SH] ACh in the presence of NPY ( 10-14-10-6 M) significantly inhibited basal ACh release (83 + 16 to 58 +-11% of control). NPY significantly inhibited ACh release stimulated by potassium (55 m&f); by adenylate cyclase agonists forskolin (lo-' M) and cholera toxin (lo-' M); and by calcitonin gene-related peptide, cholecystokinin octapeptide, and vasoactive intestinal peptide (each lo-'M). In each instance, the inhibitory effects of NPY were reversed by preincubation with pertussis toxin. Reversal of inhibitory effects by pertussis toxin suggests that the actions of NPY are mediated via an inhibitory GTPbinding protein.
INTRODUCTION
Neuropeptide Y (NPY) is a unique 37 amino acid peptide that was first isolated from the porcine brain [l] . The peptide, with expression restricted to neurons, is widely distributed in both the central and peripheral nervous systems [2-41. NPY has strong amino acid sequence homology with pancreatic polypeptide (PP) and peptide YY (PYY); the three compose a family of regulatory peptides [5, 6] . Pancreatic polypeptide immunoreactivity is found in endocrine cells of the pancreatic islets [7] . PYY immunoreactive cells have been localized within the mucosa of the gastrointestinal tract, especially the distal small intestine [S] . Within the digestive tract, NPY-positive neurons are found in the stomach, the intestine, and both the endocrine and exocrine portions of the pancreas [9, lo] .
In the guinea pig intestine, NPY -positive nerve fibers constitute approximately 5% of all neurons within the myenteric plexus (11). Garzon and associates have reported that NPY reduces the resting tension of guinea pig longitudinal muscle strips [17] . NPY was also noted to reduce the excitatory effects of cholecystokinin octapeptide via a neurally mediated mechanism [ 171. Close arterial infusion of NPY in the cat produces inhibition of colonic motility; the effect is not mediated by adrenergic receptors [18] . While the physiologic relevance of these actions of NPY within the myenteric plexus remains to be established, they suggest that the peptide may exert inhibitory actions upon enteric neurons.
The current investigation was performed to test the hypothesis that NPY inhibits release of acetylcholine from enteric neurons and to study the mechanism by which such an inhibitory action might be exerted. The studies were designed to directly test the ability of NPY to modulate acetylcholine release by using cultured myenteric plexus neurons. The involvement of neuronal adenylate cyclase in the activity of NPY was determined and the potential role of GTP-binding proteins in the observed effects was examined. Myenteric plexus neuronal culture. Primary culture of myenteric plexus neurons was accomplished by an adaptation of previously described methods [19, 201. Neonatal Duncan-Hartley guinea pigs were sacrificed, and using aseptic technique, the longitudinal smooth muscle of the teniae coli was dissected from the cecum; care was exercised not to enter the lumen of the bowel. Teniae coli were divided into 5-to 6-mm segments and were transferred to a Petri dish containing Hanks' balanced salt solution (HBSS) with highly purified collagenase (1 mg/ml) and incubated at 37°C for 1.25-1.5 hr. Tissue fragments were then transferred to fresh HBSS where, under a dissecting microscope, loosely adherent smooth muscle cells were dissected from the myenteric plexus, producing a purified myenteric plexus preparation [21] . Cell viability was maintained up to 21 days in culture.
The tissues derived from each animal were divided into 12 segments (approximately lo5 cells per segment). Isolated plexuses were explanted into tissue culture wells previously coated with poly-L-lysine (10 pg/ml). Plexuses were exposed to culture medium containing Medium 199 supplemented with nonessential amino acids, Na-pyruvate, Hepes buffer (1 M), and L-glutamate (200 mM) plus NU-Serum (lo%), glucose (5 mg/ ml), and penicillin-streptomycin solution (100 U/ml). Culture medium was exchanged every second day and antibiotics were omitted after the initial feeding. Acetylcholine release studies were performed after 5 to 7 days in culture. Cultured plexuses were used for study only if they were firmly adherent to the culture well and exhibited extensive outgrowth of dendritic processes. Each plexus culture was inspected for the presence of uniform neuronal growth. Acetylcholine release studies. The release of [3H]-labeled acetylcholine ( [3H]ACh) was studied after exposure of neurons to [3H]choline (0.2 /IM, specific activity 80 Ci/mmole) in oxygenated modified Krebs-Ringer buffer containing 50 PM physostigmine. Incubation with [3H]choline was carried out at 37°C for 60 min in a Dubnoff metabolic incubator gassed with 95% O,-5% CO,. Tissues were then washed twice with fresh buffer and allowed to recover for 30 min before exposure to agonists.
Each neuronal aggregate was exposed to only one test condition. Plexuses were exposed to NPY for 30 min before addition of agonists in those experiments utilizing coincubation with a test peptide. In experiments employing pertussis toxin, neurons were coincubated with the toxin for 18 hr prior to addition of agonists.
In all experiments, total 3H was determined to indicate transmitter release. Labeled neurons were washed and then exposed to agonists in a release medium containing the following constituents: NaCl, 118 mM, KCl, 4.7 mM; NaHPO,, 1 mM, MgCl,, .0.5 mM; CaCl,, 2.5 mM; NaHCO,, 25 &, glucose, 11.1 mM; physostigmine, 50 PM and hemicholinium, 10 FM. NaCl was adjusted to maintain osmolarity. Labeled neurons were exposed to agonists in this release medium for 15 min; the release medium was then aspirated and added to scintillation fluid. The remaining tissue was solubilized and then placed in scintillation fluid. Radioactivity was quantified by liquid scintillation spectrometry.
[3H]ACh was expressed as the percentage of total tissue 3H released into the medium.
In order to verify that the 3H released was ACh, column chromatography was used. After stimulation with the respective agonists, aliquots of release medium were applied to a cation exchange resin (Bio-Rex 70) to separate [3H]ACh and [3H]choline from other products. Unlabeled ACh and choline were applied to the column along with [14C]ACh as a marker for ACh. The column was eluted with NaHPO, buffer and radioactivity was determined. Two peaks of radioactivity were observed and greater than 90% of the increase in 3H occurring after stimulation was in the form of [3H]ACh.
Data analysis. Fractional release was calculated by expressing the radioactivity in the release medium as the percentage of total radioactivity in the tissue at the time of the experiment. The percent release of t3H]ACh over basal was calculating by dividing the fractional release produced by agonists by the spontaneous (basal) release. All results were expressed as group means f SEM. Each experiment was performed using the tissues derived from one animal; the sample size (n value) was taken as the number of guinea pigs; all experimental groups had n values of 6 to 8. Statistical analysis was performed using one-way analysis of variance. Significance was accepted as P < 0.05.
RESULTS
Effects of NPY on basal ACh release. To determine if NPY inhibits basal ACh release from cultured myenteric plexus neurons, we examined the effects of the peptide on 13H]ACh release from unstimulated neuronal plexuses. Neurons were exposed to varying concentration of NPY for 15 min in release medium to which no agonists had been added. Mean 15-min basal release was 4.5 -t 0.2% in the absence of NPY. neurons (n = 6 animals) were exposed to release medium in the absence or presence of graded concentrations of NPY for 15 min.
[sH]ACh release was quantified as the percentage released into the medium relative to the total contained within the tissue at the beginning of the experiment. *P < 0.05 vs control.
as low as lo-l4 M (Fig. 1) for use in subsequent combination with NPY, were chosen based upon these agonist dose-response studies.
To investigate potential inhibitory effects of NPY on stimulated ACh release, we coincubated NPY with the above agonists. In experiments using NPY, the peptide (lo-' M) was added to the release medium 15 min before exposure to agonist. To investigate the possibility that NPY antagonizes stimulated ACh release via activation of inhibitory (Gi) regulatory proteins, in some experiments we exposed neurons to pertussis toxin (PTX) prior to addition of NPY and agonists. Pertussis toxin has been demonstrated to ribosylate the Gi protein and thereby to block the inhibitory actions of agents utiliz- ing this mechanism. Pertussis toxin (100 rig/ml) was added 18 hr prior to [3H]choline exposure.
NPY produced significant suppression of potassiumstimulated [3H]ACh release (190 f 36% of basal) (Fig.  2) . The inhibitory effects of NPY on potassium-stimulated [3H]ACh release were reversed by preincubation with PTX (304 f 71%). Veratridine-stimulated (lo-* iU) [3H]ACh was modestly decreased after exposure to NPY (from 144 + 5% to 119 +-10%); the difference did not achieve statistical significance, however (Fig. 2) .
[3H]ACh release stimulated by forskolin ( low6 M) was abolished by preincubation with NPY (260 f 79% vs 84 f 14%). The inhibitory effects of NPY were reversed by PTX pretreatment (Fig. 3) . Similarly, NPY inhibited ACh release stimulated by CTX, decreasing fractional [3H]ACh release from 212 + 52% to 72 + 10% of basal. PTX pretreatment reversed NPY inhibition of CTX effects (152 & 12%). In contrast to the effects observed with forskolin or CTX, stimulation of [3H]ACh release by B-bromo cyclic AMP was not affected by NPY (Fig. 3) .
In the last group of experiments, the ability of NPY to inhibit neuropeptide-stimulated ACh release was tested ( Fig. 4) 
DISCUSSION
This study has clearly demonstrated that NPY inhibits the release of ACh from cultured guinea pig myenteric plexus neurons. NPY was observed to suppress basal release of [3H]ACh at concentrations as low as lo-l4 M, indicating both its potent inhibitory effects and the sensitivity of the neurons in culture to respond to exogenous peptides. NPY was also noted to inhibit [3H]ACh release stimulated by potassium-induced depolarization and by a variety of cholinergic secretagogues.
In preliminary studies, forskolin, cholera toxin, and B-bromo cyclic AMP were each shown to stimulate [3H]ACh release from myenteric plexus neurons, confirming previous reports that agents which raise intracellular CAMP levels stimulate the release of ACh from the myenteric plexus [22] . NPY was observed to inhibit the effects of forskolin, an agent which stimulates adenylate cyclase activity and the effects of CTX, an agent that activates adenylate cyclase indirectly through effects on stimulatory 
